Your browser is no longer supported. Please, upgrade your browser.
TEVA Teva Pharmaceutical Industries Limited weekly Stock Chart
TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E2950.00 EPS (ttm)0.00 Insider Own0.60% Shs Outstand1.10B Perf Week0.00%
Market Cap9.61B Forward P/E3.36 EPS next Y2.63 Insider Trans-0.05% Shs Float1.08B Perf Month-7.81%
Income4.00M PEG921.88 EPS next Q0.59 Inst Own53.20% Short Float2.26% Perf Quarter-28.22%
Sales16.48B P/S0.58 EPS this Y59.40% Inst Trans5.65% Short Ratio2.75 Perf Half Y-1.45%
Book/sh12.64 P/B0.70 EPS next Y4.90% ROA0.00% Target Price12.19 Perf Year28.63%
Cash/sh2.21 P/C4.00 EPS next 5Y3.20% ROE0.00% 52W Range6.25 - 13.76 Perf YTD-9.69%
Dividend- P/FCF10.75 EPS past 5Y-17.70% ROI-0.40% 52W High-34.12% Beta1.48
Dividend %- Quick Ratio0.70 Sales past 5Y-3.60% Gross Margin46.40% 52W Low45.04% ATR0.33
Employees40039 Current Ratio1.10 Sales Q/Q-7.30% Oper. Margin2.60% RSI (14)42.17 Volatility2.99% 3.50%
OptionableYes Debt/Eq1.90 EPS Q/Q120.20% Profit Margin0.00% Rel Volume0.68 Prev Close8.85
ShortableYes LT Debt/Eq1.78 EarningsAug 05 BMO Payout0.00% Avg Volume8.91M Price9.06
Recom2.80 SMA200.66% SMA50-11.89% SMA200-15.06% Volume4,339,709 Change2.43%
Aug-06-20Upgrade Barclays Underweight → Equal Weight $10 → $13
Jul-27-20Resumed Goldman Neutral $12
Jun-01-20Upgrade SunTrust Hold → Buy
Apr-24-20Resumed Citigroup Neutral $10
Apr-06-20Upgrade UBS Neutral → Buy $14 → $12
Feb-24-20Downgrade Edward Jones Hold → Sell
Nov-12-19Upgrade JP Morgan Underweight → Neutral $8
Oct-17-19Upgrade Gabelli & Co Hold → Buy
Aug-07-19Downgrade Evercore ISI Outperform → In-line
Jul-19-19Initiated Wolfe Research Peer Perform
Jul-15-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-10-19Resumed Credit Suisse Neutral
Jul-05-19Upgrade Argus Hold → Buy
Jun-11-19Initiated Barclays Underweight $8
Jun-03-19Upgrade Oppenheimer Perform → Outperform $12
May-30-19Downgrade BofA/Merrill Buy → Underperform
May-28-19Downgrade UBS Buy → Neutral
Mar-20-19Initiated SunTrust Hold
Mar-07-19Resumed UBS Buy $22
Mar-06-19Downgrade Morgan Stanley Overweight → Equal-Weight $17
Sep-28-20 10:45PM  
07:00PM  
01:16PM  
08:45AM  
Sep-27-20 03:12AM  
Sep-25-20 06:58PM  
10:00AM  
09:19AM  
Sep-24-20 05:22PM  
03:06PM  
10:55AM  
Sep-23-20 08:20PM  
07:13PM  
Sep-22-20 07:31AM  
Sep-21-20 08:00AM  
Sep-19-20 03:49PM  
Sep-16-20 07:21AM  
Sep-15-20 08:00AM  
06:06AM  
12:18AM  
Sep-14-20 08:00AM  
Sep-08-20 11:57AM  
08:00AM  
Sep-02-20 07:36PM  
01:21PM  
Aug-26-20 03:35PM  
02:20PM  
12:50PM  
11:35AM  
08:55AM  
08:33AM  
03:15AM  
12:00AM  
Aug-25-20 10:42PM  
08:39PM  
04:22PM  
03:21PM  
03:20PM  
03:08PM  
03:01PM  
12:56PM  
Aug-24-20 07:24PM  
Aug-22-20 11:40AM  
Aug-19-20 11:37AM  
08:31AM  
08:00AM  
Aug-18-20 11:03PM  
05:04PM  
03:32PM  
03:25PM  
02:07PM  
02:01PM  
01:38PM  
11:59AM  
11:53AM  
10:19AM  
10:01AM  
Aug-13-20 01:15PM  
Aug-11-20 02:12PM  
Aug-06-20 01:42PM  
01:22PM  
09:09AM  
Aug-05-20 04:47PM  
07:59AM  
07:45AM  
07:30AM  
07:19AM  
07:11AM  
07:10AM  
07:00AM  
02:01AM  
Aug-03-20 11:26AM  
Jul-31-20 03:01AM  
Jul-30-20 02:00AM  
Jul-29-20 08:00AM  
Jul-27-20 02:27PM  
Jul-16-20 05:34PM  
Jul-15-20 05:51AM  
Jul-13-20 08:30AM  
08:00AM  
Jul-12-20 12:53PM  
Jul-09-20 04:00PM  
09:26AM  
Jul-08-20 11:52AM  
Jul-05-20 06:56AM  
Jul-03-20 08:07AM  
Jul-02-20 05:51AM  
Jul-01-20 11:50AM  
11:30AM  
07:21AM  
Jun-18-20 08:00AM  
Jun-15-20 03:20PM  
02:28PM  
11:50AM  
11:30AM  
08:00AM  
Jun-12-20 05:50PM  
Jun-09-20 07:30AM  
06:06AM  
Jun-08-20 04:14PM  
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Daniell RichardExec. VP, European CommercialSep 09Sale8.983332,99210,765Sep 10 09:04 AM
Crane Rosemary ADirectorAug 11Sale11.902,86034,03833,509Aug 13 04:07 PM
Griffin Deborah AChief Accounting OfficerMar 17Sale7.169446,7620Mar 19 08:09 AM
Stark David MatthewExec. VP Chief Legal OfficerMar 17Sale7.162,35916,8992,974Mar 19 07:38 AM
O'Grady Brendan P.EVP, North America CommercialMar 17Sale7.164703,36714,868Mar 19 07:37 AM
Nazzi GianfrancoEVP, International MarketsMar 17Sale7.173452,47419,844Mar 19 07:36 AM
Fridriksdottir HafrunExecutive VP, Global R&DMar 17Sale7.165143,68245,561Mar 19 07:33 AM
Daniell RichardExec. VP, European CommercialMar 17Sale7.176164,41810,400Mar 19 07:31 AM
Griffin Deborah AChief Accounting OfficerMar 04Sale11.234,80753,9800Mar 05 08:16 AM
O'Grady Brendan P.EVP, North America CommercialMar 03Sale11.374635,26214,159Mar 05 08:13 AM
Nazzi GianfrancoEVP, International MarketsMar 03Sale11.775486,44819,315Mar 05 08:11 AM
Daniell RichardExec. VP, European CommercialMar 03Sale11.7799111,6609,719Mar 05 08:07 AM
Griffin Deborah AChief Accounting OfficerMar 03Sale11.371,16613,2530Mar 04 06:39 AM
Griffin Deborah AChief Accounting OfficerMar 02Sale11.602,94134,1120Mar 04 06:39 AM
Drape EricExecutive VP Global OperationsFeb 19Sale12.518,000100,08021,494Feb 20 07:17 PM
Fridriksdottir HafrunExecutive VP, Global R&DFeb 14Sale12.1411,472139,29545,061Feb 18 07:23 AM
Drape EricExecutive VP Global OperationsFeb 14Sale12.148,14098,78529,494Feb 18 07:22 AM
Stark David MatthewExec. VP Chief Legal OfficerFeb 14Sale12.1417,016206,6122,974Feb 18 07:26 AM
Sabag MarkSee "Remarks" belowFeb 13Sale13.0372,131939,7600Feb 18 07:25 AM
Stark David MatthewExec. VP Chief Legal OfficerFeb 10Sale12.2412,538153,4712,974Feb 11 07:06 AM
O'Grady Brendan P.EVP, North America CommercialFeb 10Sale12.274,79958,88413,456Feb 11 07:02 AM
Nazzi GianfrancoEVP, Growth Markets CommercialFeb 10Sale12.244,15550,86418,464Feb 11 07:01 AM
Fridriksdottir HafrunExecutive VP, Global R&DFeb 10Sale12.275,54468,02533,330Feb 11 06:57 AM
Drape EricExecutive VP Global OperationsFeb 10Sale12.243,14438,48820,618Feb 11 06:56 AM
Dethlefs SvenEVP Global Marketing&PortfolioFeb 10Sale12.275,66969,55918,061Feb 11 06:53 AM
Daniell RichardExec. VP, European CommercialFeb 10Sale12.246,19975,8868,612Feb 11 06:52 AM
Fridriksdottir HafrunExecutive VP, Global R&DDec 31Sale9.922,45924,39622,754Jan 02 06:08 AM
Fridriksdottir HafrunExecutive VP, Global R&DDec 02Sale10.494,31045,21420,573Dec 03 06:32 AM
McClellan Michael JamesEVP, Chief Financial OfficerNov 05Sale8.832422,13815,898Nov 06 06:46 AM